In vitro evaluation of potential transporter-mediated drug interactions of evogliptin

Biopharmaceutics & Drug Disposition
Dae Y LeeHyun J Shim

Abstract

To date, little is known about the transporter-mediated drug-drug interaction (DDI) potential of evogliptin, a novel DPP-4 inhibitor. The objective of this study was to evaluate the DDI potential of evogliptin using various in vitro assays in transporter-expressing cell lines. After incubating evogliptin with cells overexpressing OAT1, OAT3, OCT2, OATP1B1 and OATP1B3, there was no notable cellular accumulation of evogliptin (fold accumulation, 0.41-1.86). In bidirectional transport assays using a Caco-2 cell monolayer, a high efflux ratio (ER, 522) of evogliptin was observed, which was significantly decreased (97.96%) in the presence of a potent P-gp inhibitor. In assays using MDCKII-BCRP cell monolayers, by contrast, a low net ER (1.16-1.26) was found. In similar cellular uptake and bidirectional studies with probe substrates of P-gp, BCRP, OAT1, OAT3, OCT2, OATP1B1 and OATP1B3, the active transport of the substrates was not significantly suppressed by evogliptin. These results suggest that evogliptin may be a substrate of P-gp, but not a substrate of BCRP, OAT1B1, OAT1B3, OAT1, OAT3 or OCT2, and not an inhibitor of any of these transporters. Therefore, it could be concluded that evogliptin has some DDI potential involving P-g...Continue Reading

References

Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·M MüllerP L Jansen
Mar 14, 2001·Journal of Biochemical and Biophysical Methods·B A Mungall, C C Pollitt
Aug 11, 2001·Cellular and Molecular Life Sciences : CMLS·T LitmanS E Bates
Jan 5, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hiroyuki Kusuhara, Yuichi Sugiyama
May 26, 2004·The Journal of Pharmacology and Experimental Therapeutics·Masaru HiranoYuichi Sugiyama
Jul 15, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Maki ShimizuYuichi Sugiyama
Feb 4, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jarkko RautioJoseph W Polli
Mar 2, 2010·Nature Reviews. Drug Discovery·UNKNOWN International Transporter ConsortiumLei Zhang
Aug 10, 2010·Clinical Pharmacokinetics·André J Scheen
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Jul 27, 2011·Pharmacogenomics·Fabian Müller, Martin F Fromm
Apr 6, 2012·Trends in Pharmacological Sciences·Aleksi TornioJanne T Backman
Oct 18, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Naoki IshiguroOlaf Schaefer
Jun 5, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Eric L ReynerBill J Smith
Jan 1, 2011·Pharmaceutics·Sabine KlattJörg König
Jul 2, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Li LiSu Zeng
Sep 26, 2014·Biological Trace Element Research·Cesar Augusto Sam Tiago Vilanova-CostaElisângela de Paula Silveira-Lacerda

❮ Previous
Next ❯

Citations

May 1, 2019·The Journal of Pharmacy and Pharmacology·Suqin FengLing Wang
Apr 11, 2020·Translational and Clinical Pharmacology·Namyi GuTae-Eun Kim
Nov 28, 2020·British Journal of Clinical Pharmacology·Taegon HongMin Soo Park

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.